Planet Green Holdings Expands into the Immune-Health Market
In a bold move to solidify its presence in the booming immune-health sector,
Planet Green Holdings Corp. (NYSE American: PLAG) announced the acquisition of a promising chewable tablet product featuring lactoferrin, bovine colostrum, and vitamin C. This strategic acquisition, executed through its wholly-owned subsidiary
Hubei Taihe Biotechnology Co., Ltd. (referred to as Taihe Bio), marks a significant step forward for Planet Green as it aims to meet growing consumer demands for immune support.
A Profitable Partnership
The deal includes a technology transfer agreement with
Harbin Aikesailun Biotechnology Co., Ltd., allowing Taihe Bio to acquire not just the product, but also the proprietary formulation, production technology, quality standards, and essential technical know-how. This acquisition is particularly advantageous as it comes with an existing health food registration certificate in China, a process that is often lengthy and costly for new products. As stated by
Mr. Bin Zhou, Chairman of Planet Green, this acquisition serves as a natural extension to their lactoferrin strategy, enabling them to swiftly capitalize on China's growth in the lactoferrin market.
Lactoferrin, a naturally occurring protein predominantly found in colostrum – the first milk produced by mammals after giving birth – is renowned for its immune-boosting properties. The combination of lactoferrin with bovine colostrum and vitamin C in a convenient chewable format positions Planet Green favorably to cater to health-conscious consumers in China.
Efficient Market Entry
By utilizing an asset-light model and licensed contract manufacturers instead of building its own production facilities, Taihe Bio aims to keep capital expenditure low while speeding up the route to market. This approach not only allows them to focus on quality and efficiency but also to reduce operational risks traditionally associated with manufacturing.
As the global lactoferrin market is projected to grow significantly, from approximately $278 million in 2026 to an estimated $519 million by 2034, Planet Green is strategically positioning itself to become a major player in this lucrative landscape. Reflecting on market opportunities, data from
Grand View Research indicates that China held the largest share of this market in 2025, further emphasizing the importance of Taihe Bio’s acquisition.
Future Developments
Following the completion of transfer agreements, including technical documentation and process support, Taihe Bio plans to apply to China's State Administration for Market Regulation (SAMR) to finalize the registration transfer. This process, pending regulatory approval, will enable Taihe Bio to engage contract manufacturers with the necessary production licenses, paving the way for commercial production of the newly acquired product.
Planet Green’s conviction in its lactoferrin sourcing, marketing, and distribution strategy fortifies its chewable immunity tablet program, which promises to resonate well in the market.
About Planet Green Holdings
Based in
Flushing, New York, Planet Green Holdings is a diversified holding company with interests in various sectors, including consumer products and online advertising. The company's commitment to delivering innovative health solutions aligns with the increasing consumer focus on wellness and sustainability. For more insights into their business and offerings, visit
Planet Green Holdings.
In conclusion, Planet Green's acquisition of the advanced immune-support tablet not only enhances its product portfolio but also strategically positions it to thrive in the expanding health market in China. As the demand for immune health solutions continues to rise, Planet Green's proactive approach could lead to substantial growth and success in the years ahead.